María Eugenia Giorgi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
María Eugenia Giorgi has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Rosa M. de Lederkremer
CIHIDECAR, Departamento de Química Orgánica, Facultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires, Ciudad Universitaria, Pabellón II, 1428 Buenos Aires, Argentina
7 shared publications Rosa M. de Lederkremer
Universidad de Buenos Aires. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro de Investigaciones en Hidratos de Carbono (CIHIDECAR). Facultad de Ciencias Exactas y Naturales. Departamento de Química Orgánica, Buenos Aires, Argentina
4 shared publications- Carla Marino
Universidad de Buenos Aires (UBA), Facultad de Ciencias Exactas y Naturales, Departamento de Química Orgánica, Intendente Güiraldes 2160, C1428EHA Buenos Aires, Argentina
3 shared publications Rosalía Agusti
CIHIDECAR-CONICET, Departamento de Química Orgánica, Facultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires, Pabellón II, Ciudad Universitaria, 1428 Buenos Aires, Argentina
3 shared publicationsRosalía Agustí
CIHIDECAR, Departamento de Química Orgánica, Facultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires, Ciudad Universitaria, Pabellón II, 1428 Buenos Aires, Argentina
3 shared publications- Alberto Carlos C. Frasch
Instituto de Investigaciones Biotecnológicas IIB-INTECH, CONICET-UNSAM, San Martin, Argentina
2 shared publications
Latest Publications
- 14 December 2022
- Published by Elsevier in Plant Physiology and Biochemistry
- Vol. 194, 638-642
Presence of inulin in sunflower (Helianthus annuus L.) grown under high irradiance
- 14 December 2022
- Published by Elsevier in Plant Physiology and Biochemistry
- Vol. 194, 638-642
Presence of inulin in sunflower (Helianthus annuus L.) grown under high irradiance
- 9 September 2022
- Published by American Chemical Society (ACS) in ACS Infectious Diseases
- Vol. 8 (11) , 2207-2222
The α-Galactosyl Carbohydrate Epitope in Pathogenic Protozoa
The α-gal epitope, which refers to the carbohydrate α-d-Galp-(1 → 3)-β-d-Galp-(1 → 4)-d-GlcNAc-R, was first described in the glycoconjugates of mammals other than humans. Evolution caused a mutation that resulted in the inactivation of the α-1,3-galactosyltransferase gene. For that reason, humans produce antibodies against α-d-Galp containing glycoproteins and glycolipids of other species. We summarize here the glycoconjugates with α-d-Galp structures in Trypanosoma, Leishmania, and Plasmodium pathogenic protozoa. These were identified in infective stages of Trypanosoma cruzi and in Plasmodium sporozoites. In Leishmania, α-d-Galp is linked differently in the glycans of glycoinositolphospholipids (GIPLs). Chemically synthesized neoglycoconjugates have been proposed as diagnostic tools and as antigens for vaccines. Several syntheses reported for the α-gal trisaccharide, also called the Galili epitope, and the glycans of GIPLs found in Leishmania, the preparation of neoglycoconjugates, and the studies in which they were involved are also included in this Review.
- 9 September 2022
- Published by American Chemical Society (ACS) in ACS Infectious Diseases
- Vol. 8 (11) , 2207-2222
The α-Galactosyl Carbohydrate Epitope in Pathogenic Protozoa
The α-gal epitope, which refers to the carbohydrate α-d-Galp-(1 → 3)-β-d-Galp-(1 → 4)-d-GlcNAc-R, was first described in the glycoconjugates of mammals other than humans. Evolution caused a mutation that resulted in the inactivation of the α-1,3-galactosyltransferase gene. For that reason, humans produce antibodies against α-d-Galp containing glycoproteins and glycolipids of other species. We summarize here the glycoconjugates with α-d-Galp structures in Trypanosoma, Leishmania, and Plasmodium pathogenic protozoa. These were identified in infective stages of Trypanosoma cruzi and in Plasmodium sporozoites. In Leishmania, α-d-Galp is linked differently in the glycans of glycoinositolphospholipids (GIPLs). Chemically synthesized neoglycoconjugates have been proposed as diagnostic tools and as antigens for vaccines. Several syntheses reported for the α-gal trisaccharide, also called the Galili epitope, and the glycans of GIPLs found in Leishmania, the preparation of neoglycoconjugates, and the studies in which they were involved are also included in this Review.
- Open Access
The Glycan Structure of T. cruzi mucins Depends on the Host. Insights on the Chameleonic Galactose
Trypanosoma cruzi, the protozoa that causes Chagas disease in humans, is transmitted by insects from the Reduviidae family. The parasite has developed the ability to change the structure of the surface molecules, depending on the host. Among them, the mucins are the most abundant glycoproteins. Structural studies have focused on the epimastigotes and metacyclic trypomastigotes that colonize the insect, and on the mammal trypomastigotes. The carbohydrate in the mucins fulfills crucial functions, the most important of which being the accepting of sialic acid from the host, a process catalyzed by the unique parasite trans-sialidase. The sialylation of the parasite influences the immune response on infection. The O-linked sugars have characteristics that differentiate them from human mucins. One of them is the linkage to the polypeptide chain by the hexosamine, GlcNAc, instead of GalNAc. The main monosaccharide in the mucins oligosaccharides is galactose, and this may be present in three configurations. Whereas β-d-galactopyranose (β-Galp) was found in the insect and the human stages of Trypanosoma cruzi, β-d-galactofuranose (β-Galf) is present only in the mucins of some strains of epimastigotes and α-d-galactopyranose (α-Galp) characterizes the mucins of the bloodstream trypomastigotes. The two last configurations confer high antigenic properties. In this review we discuss the different structures found and we pose the questions that still need investigation on the exchange of the configurations of galactose.
Open AccessThe Glycan Structure of T. cruzi mucins Depends on the Host. Insights on the Chameleonic Galactose
Trypanosoma cruzi, the protozoa that causes Chagas disease in humans, is transmitted by insects from the Reduviidae family. The parasite has developed the ability to change the structure of the surface molecules, depending on the host. Among them, the mucins are the most abundant glycoproteins. Structural studies have focused on the epimastigotes and metacyclic trypomastigotes that colonize the insect, and on the mammal trypomastigotes. The carbohydrate in the mucins fulfills crucial functions, the most important of which being the accepting of sialic acid from the host, a process catalyzed by the unique parasite trans-sialidase. The sialylation of the parasite influences the immune response on infection. The O-linked sugars have characteristics that differentiate them from human mucins. One of them is the linkage to the polypeptide chain by the hexosamine, GlcNAc, instead of GalNAc. The main monosaccharide in the mucins oligosaccharides is galactose, and this may be present in three configurations. Whereas β-d-galactopyranose (β-Galp) was found in the insect and the human stages of Trypanosoma cruzi, β-d-galactofuranose (β-Galf) is present only in the mucins of some strains of epimastigotes and α-d-galactopyranose (α-Galp) characterizes the mucins of the bloodstream trypomastigotes. The two last configurations confer high antigenic properties. In this review we discuss the different structures found and we pose the questions that still need investigation on the exchange of the configurations of galactose.
- 1 May 2019
- Published by Elsevier in Carbohydrate Research
- Vol. 478, 58-67
Synthesis and characterization of α-d-Galp-(1 → 3)-β-d-Galp epitope-containing neoglycoconjugates for chagas disease serodiagnosis
- 1 May 2019
- Published by Elsevier in Carbohydrate Research
- Vol. 478, 58-67
Synthesis and characterization of α-d-Galp-(1 → 3)-β-d-Galp epitope-containing neoglycoconjugates for chagas disease serodiagnosis
- 1 October 2017
- Published by Elsevier in Carbohydrate Research
- Vol. 450, 30-37
Synthesis of a model trisaccharide for studying the interplay between the anti α-Gal antibody and the trans-sialidase reactions in Trypanosoma cruzi
- 1 October 2017
- Published by Elsevier in Carbohydrate Research
- Vol. 450, 30-37
Synthesis of a model trisaccharide for studying the interplay between the anti α-Gal antibody and the trans-sialidase reactions in Trypanosoma cruzi
- Open Access
- 1 March 2015
- Published by Elsevier in Bioorganic & Medicinal Chemistry
- Vol. 23 (6) , 1213-1222
Synthesis of the O-linked hexasaccharide containing β-d-Galp-(1→2)-d-Galf in Trypanosoma cruzi mucins. Differences on sialylation by trans-sialidase of the two constituent hexasaccharides
- 1 March 2015
- Published by Elsevier in Bioorganic & Medicinal Chemistry
- Vol. 23 (6) , 1213-1222
Open AccessSynthesis of the O-linked hexasaccharide containing β-d-Galp-(1→2)-d-Galf in Trypanosoma cruzi mucins. Differences on sialylation by trans-sialidase of the two constituent hexasaccharides
- Open Access
- 25 June 2014
- Published by Beilstein Institut in Beilstein Journal of Organic Chemistry
- Vol. 10 (1) , 1433-1444
Carbohydrate PEGylation, an approach to improve pharmacological potency
Conjugation with polyethylene glycol (PEG), known as PEGylation, has been widely used to improve the bioavailability of proteins and low molecular weight drugs. The covalent conjugation of PEG to the carbohydrate moiety of a protein has been mainly used to enhance the pharmacokinetic properties of the attached protein while yielding a more defined product. Thus, glycoPEGylation was successfully applied to the introduction of a PEGylated sialic acid to a preexisting or enzymatically linked glycan in a protein. Carbohydrates are now recognized as playing an important role in host–pathogen interactions in protozoal, bacterial and viral infections and are consequently candidates for chemotherapy. The short in vivo half-life of low molecular weight glycans hampered their use but methods for the covalent attachment of PEG have been less exploited. In this review, information on the preparation and application of PEG-carbohydrates, in particular multiarm PEGylation, is presented.
- 25 June 2014
- Published by Beilstein Institut in Beilstein Journal of Organic Chemistry
- Vol. 10 (1) , 1433-1444
Open AccessCarbohydrate PEGylation, an approach to improve pharmacological potency
Conjugation with polyethylene glycol (PEG), known as PEGylation, has been widely used to improve the bioavailability of proteins and low molecular weight drugs. The covalent conjugation of PEG to the carbohydrate moiety of a protein has been mainly used to enhance the pharmacokinetic properties of the attached protein while yielding a more defined product. Thus, glycoPEGylation was successfully applied to the introduction of a PEGylated sialic acid to a preexisting or enzymatically linked glycan in a protein. Carbohydrates are now recognized as playing an important role in host–pathogen interactions in protozoal, bacterial and viral infections and are consequently candidates for chemotherapy. The short in vivo half-life of low molecular weight glycans hampered their use but methods for the covalent attachment of PEG have been less exploited. In this review, information on the preparation and application of PEG-carbohydrates, in particular multiarm PEGylation, is presented.
- Open Access
- 30 May 2012
- Published by Oxford University Press (OUP) in Glycobiology
- Vol. 22 (10) , 1363-1373
Improved bioavailability of inhibitors of Trypanosoma cruzi trans-sialidase: PEGylation of lactose analogs with multiarm polyethyleneglycol
The trans-sialidase of Trypanosoma cruzi (TcTS) catalyzes the transfer of sialic acid from host glycoconjugates to terminal β-galactopyranosides in the mucins of the parasite. During infection, the enzyme is actively shed by the parasite to the bloodstream inducing hematological alterations. Lactitol prevents cell apoptosis caused by the TcTS, although it is rapidly eliminated from the circulatory system. Linear polyethyleneglycol (PEG) conjugates of lactose analogs were prepared but their clearance from blood was still quite fast. With the aim of improving their circulating half-lives in vivo, we now synthesized covalent conjugates of eight-arm PEG. The star-shape of these conjugates allows an increase in the molecular weight together with the loading of the active sugar. Two approaches were used for PEGylation of disaccharide derivatives containing β-d-Galp as the non-reducing unit. (1) Amide formation between benzyl β-d-galactopyranosyl-(1→6)-2-amino-2-deoxy-α-d-glucopyranoside and a succinimide-activated PEG. (2) Conjugation of lactobionolactone with amino end-functionalized PEG. Two 8-arm PEG derivatives (20 and 40 kDa) were used for each sugar. Substitution of all arms was proved by 1H nuclear magnetic resonance (NMR) spectroscopy. The bioavailability of the conjugates in mice plasma was considerably improved with respect to the 5 kDa linear PEG conjugates retaining their inhibitory properties.
- 30 May 2012
- Published by Oxford University Press (OUP) in Glycobiology
- Vol. 22 (10) , 1363-1373
Open AccessImproved bioavailability of inhibitors of Trypanosoma cruzi trans-sialidase: PEGylation of lactose analogs with multiarm polyethyleneglycol
The trans-sialidase of Trypanosoma cruzi (TcTS) catalyzes the transfer of sialic acid from host glycoconjugates to terminal β-galactopyranosides in the mucins of the parasite. During infection, the enzyme is actively shed by the parasite to the bloodstream inducing hematological alterations. Lactitol prevents cell apoptosis caused by the TcTS, although it is rapidly eliminated from the circulatory system. Linear polyethyleneglycol (PEG) conjugates of lactose analogs were prepared but their clearance from blood was still quite fast. With the aim of improving their circulating half-lives in vivo, we now synthesized covalent conjugates of eight-arm PEG. The star-shape of these conjugates allows an increase in the molecular weight together with the loading of the active sugar. Two approaches were used for PEGylation of disaccharide derivatives containing β-d-Galp as the non-reducing unit. (1) Amide formation between benzyl β-d-galactopyranosyl-(1→6)-2-amino-2-deoxy-α-d-glucopyranoside and a succinimide-activated PEG. (2) Conjugation of lactobionolactone with amino end-functionalized PEG. Two 8-arm PEG derivatives (20 and 40 kDa) were used for each sugar. Substitution of all arms was proved by 1H nuclear magnetic resonance (NMR) spectroscopy. The bioavailability of the conjugates in mice plasma was considerably improved with respect to the 5 kDa linear PEG conjugates retaining their inhibitory properties.
- 1 September 2011
- Published by Elsevier in Carbohydrate Research
- Vol. 346 (12) , 1389-1393
Trans-sialidase and mucins of Trypanosoma cruzi: an important interplay for the parasite
- 1 September 2011
- Published by Elsevier in Carbohydrate Research
- Vol. 346 (12) , 1389-1393
Trans-sialidase and mucins of Trypanosoma cruzi: an important interplay for the parasite
- Open Access
- 13 March 2011
- Published by ARKAT USA, Inc. in Arkivoc
- Vol. 2011 (7) , 260-271
Synthesis of oseltamivir conjugates with lactose analogs for inhibition studies on Trypanosoma cruzi trans-sialidase
- 13 March 2011
- Published by ARKAT USA, Inc. in Arkivoc
- Vol. 2011 (7) , 260-271
Open AccessSynthesis of oseltamivir conjugates with lactose analogs for inhibition studies on Trypanosoma cruzi trans-sialidase